Sir
There is now a great deal of evidence implicating the involvement of acetylcholine in cognitive processes relevant to schizophrenia (Friedman et al, 1999) . This in turn provides potential for remediation strategies by manipulation of acetylcholine and/or its receptors. In response to our recently published paper in this journal (Zavitsanou et al, 2004) , Brian Dean provided evidence that muscarinic M1 receptor agonism might be a possible treatment for cognitive deficits in schizophrenia.
Cognitive processes relevant to schizophrenia are mediated by the anterior cingulate cortex (ACC, Brodman's area 24), which plays an important role in attention control (Bush et al, 2000) and the prefrontal cortex, which is involved in working memory and executive function (Goldman-Rakic, 1987) . In our recently published paper (Zavitsanou et al, 2004) , we reported a decrease in [ Unfortunately, without specific ligands it is difficult to assign a specific muscarinic receptor subtype to deficits observed in both post-mortem and neuroimaging studies (eg Raedler et al, 2003) . Whereas in BA9, a decrease in [ 3 H]pirenzepine binding was associated with a decrease in M1 but not M4 receptor protein and mRNA (Dean et al, 2002) , no data are available to support a similar association in the ACC. Studies with muscarinic receptor knockout mice have begun to offer some enhanced understanding of the role of muscarinic receptor subtypes in cognition and psychosis. In this context, it is of interest that M1 receptor knockout mice show abnormalities in memory-relative cognitive behaviors (Anagnostaras et al, 2003) , whereas mice lacking the M4 receptor show a deficit in prepulse inhibition of the startle reflex, a measure of attention (Felder et al, 2001) .
Recent studies using acetylcholinesterase inhibitors support the notion that activation of cholinergic receptors would be an effective approach to reversing the cognitive deficits in schizophrenia (Buchanan et al, 2003) . As acetycholinesterase inhibitors are nonspecific in their effects, targeting both nicotinic and muscarinic receptors, it is difficult to assess the potential of each subtype as a target for remediation strategies and its role in side effects. The genetic study by Liao et al (2003) suggests that involvement of M1 receptors might be critical in the genesis of cognitive deficits in schizophrenia, and therefore M1 receptor agonism might be a good remediation strategy for the treatment of the cognitive dysfunction in schizophrenia.
In vivo neuroimaging studies using subtype selective radioligands with appropriate potency, efficacy, and pharmacokinetic properties are necessary for the better understanding of the role of each muscarinic receptor in cognitive processes. Future development of a muscarinic agonist that can produce improvements in cognitive performance without producing side effects is warranted and may prove useful in treating the cognitive deficits associated with schizophrenia. However, since abnormalities in noncholinergic systems that are modulated by acetylcholine have been reported in the ACC in schizophrenia , pharmacologic treatment of cognitive symptoms through manipulations of these neurotransmitter systems merits investigation.
